Cresence AS 

Cresence AS develops new neuroregenerative drugs for neurodegenerative disorders with unmet needs


Francois Curtin (See Profile)




Prototyping, preclinical



Epidermal Growth Factor (EGF) is a new drug efficacious and safe for targeted administrations for unmet medical needs

EGF is neuroregenerative with a dual mode of action stimulating myelin regeneration & regulating macrophage polarisation

EGF is indicated for treatment of orphan/rare diseases: progressive Multiple Sclerosis, Guillain Barre Syndrome and CIDP

Cresence AS employs a virtual corporate structure thanks to the experience and network of its management team

IP Type Status Time Countries Link What protects?
Patent Pending
  • Australia
  • Austria
  • Belgium
  • Canada
  • China
  • Denmark
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Russia
  • South Korea
  • Spain
  • Switzerland
  • USA
  • United Kingdom The invention relates to a (poly)peptide having Epidermal Growth Factor (EGF)-activity or a nucleic acid encoding said (poly)peptide for use in treating or preventing a demyelinating and/or neurodegenerating

This information is confidential, do not share or copy.

Under evaluation at least till: 22nd March

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar